DNL-343 is a small molecule commercialized by Denali Therapeutics, with a leading Phase III program in Amyotrophic Lateral Sclerosis. According to Globaldata, it is involved in 7 clinical trials, of which 6 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of DNL-343’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for DNL-343 is expected to reach an annual total of $35 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
DNL-343 Overview
DNL-343 is under development for the treatment of amyotrophic lateral sclerosis (ALS). The drug candidate acts by targeting eukaryotic translation initiation factor 2 subunit beta (EIF2B). It is administered through oral route.
It was also under development for the treatment of frontotemporal dementia (FTD).
Denali Therapeutics Overview
Denali Therapeutics is a clinical-stage biopharmaceutical company that develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. The company’s proprietary technology platform, which develops brain-penetrant therapies based on enzyme transport vehicle, antibody transport vehicle, protein transport vehicleand oligonucleotide transport vehicle. Its pipeline products include Iduronate 2-sulfatase, LRRK2, Progranulin, Sulfamidase, Alpha-L-iduronidase, eIF2B and RIPK1 (Peripheral). The company’s pipeline products are intended for the treatment of Alzheimer’s disease, Parkinson’s disease, lysosomal storage disorder disease, neurodegeneration, amyotrophic lateral sclerosis and other indications. Denali Therapeutics is headquartered in San Francisco, California, the US.
The company reported revenues of (US Dollars) US$330.5 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$108.5 million in FY2022. The operating loss of the company was US$196.7 million in FY2023, compared to an operating loss of US$340.7 million in FY2022. The net loss of the company was US$145.2 million in FY2023, compared to a net loss of US$326 million in FY2022.
For a complete picture of DNL-343’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
